Stock comparison
Aurinia Pharmaceuticals
LeMaitre Vascular
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
AUPH
Aurinia Pharmaceuticals
Market cap
$1.96B
Sector
Healthcare
LMAT
LeMaitre Vascular
Market cap
$2.23B
Sector
Healthcare
Overall winner
LeMaitre Vascular LMAT
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | AUPH | LMAT | Winner |
|---|---|---|---|
| Warren Buffett | 56C | 77B | LMAT |
| Benjamin Graham | 54D | 89A | LMAT |
| Philip Fisher | 59C | 81C | LMAT |
| Peter Lynch | 81A | 67B | AUPH |
| Joel Greenblatt | 63C | 56D | AUPH |
| Charlie Munger | 49D | 68D | LMAT |
| Terry Smith | 48D | 69D | LMAT |
Side-by-side metrics
| Metric | AUPH | LMAT |
|---|---|---|
| Market cap | $1.96B | $2.23B |
| P/E (TTM) | 6.9x | 37.1x |
| EV/EBIT | 19.4x | 36.6x |
| ROIC (TTM) | 18.99% | 9.43% |
| Gross margin | 89.74% | 72.39% |
| Net margin | 99.97% | 24.35% |
| Revenue CAGR 5y | 57.84% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
AUPH leads on
- P/E (TTM)6.9xvs 37.1x+81%
- Revenue CAGR 5y57.84%vs 12.75%+78%
- Net margin99.97%vs 24.35%+76%
- Debt / Equity0.1xvs 0.5x+74%
LMAT leads on
- Dividend yield0.84%vs 0.0%+100%
- Market cap$2.23Bvs $1.96B+12%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.